HCP Media Library

Watch and listen to learn more about colorectal cancer (CRC) screening.

Dr. Fenton Shares His Story of CRC Screening

See how Dr. Fenton screened with Cologuard® and caught CRC early, and how it impacted his approach to CRC screening

  •  

Dr. Fenton is a primary care physician at Beth Israel Deaconess Medical Center in Salem, NH. He practices family medicine, where he recommends CRC screening to his eligible patients. After becoming eligible himself, he screened for CRC with Cologuard. The result came back positive, prompting a follow-up with a colonoscopy. The colonoscopy revealed that although his cancer was very close to his lymph nodes, it was stage I and treatable. Dr. Fenton is now cancer-free. Since then, he has a renewed sense of urgency when it comes to regular screening and uses his own story to offer CRC screening to patients.

Dr. Durado Brooks Reviews the Current State of CRC Screening

Watch Dr. Brooks discuss various topics pertaining to CRC and Cologuard

  •  
  •  
  •  
  •  
  •  
  • play-icon
    pause-icon
    video-icon

    now-playing

    Dr. Brooks urges eligible adults to get screened for CRC in order to bring us closer to the National Colorectal Cancer Roundtable screening goal.
  • play-icon
    pause-icon
    video-icon

    now-playing

    Dr. Brooks discusses CRC survival rates and how they can be impacted by offering choice.
  • play-icon
    pause-icon
    video-icon

    now-playing

    Dr. Brooks introduces the pivotal Cologuard trial, written by Imperiale et al and published in The New England Journal of Medicine in 2014.
  • play-icon
    pause-icon
    video-icon

    now-playing

    Dr. Brooks dives into the results of the pivotal Cologuard trial.
  • play-icon
    pause-icon
    video-icon

    now-playing

    Dr. Brooks explores the 4 questions doctors need to answer in order to determine whether or not a patient is eligible for Cologuard.

Durado Brooks, MD, MPH, is the Deputy Chief Medical Officer at Exact Sciences.

In this role he serves as liaison for scientifically driven engagements, and contributes to the design, conduct, and reporting of innovative research. Dr. Brooks leads strategic outreach and collaboration, designed to increase cancer screening and improve outcomes in traditionally underserved populations. An internist by training, he has spent much of his career working to enhance the role of prevention in primary care, and to improve care for medically underserved populations. An Ohio native, Dr. Brooks received his medical degree from Wright State University School of Medicine in Dayton, Ohio, where he subsequently completed his internal medicine residency and served as Chief Resident. Additionally, Dr. Brooks holds a Master of Public Health (MPH) degree from the Harvard School of Public Health. Prior to joining Exact Sciences, Dr. Brooks was the Vice President of Prevention and Early Detection for the American Cancer Society. His work involved creating strategies to improve the prevention and early detection of cancer, and to assist those who are diagnosed with the disease.

  • The U.S. Preventive Services Task Force (USPSTF) recommends starting CRC screening for average-risk patients at age 45 (Grade B recommendation) 1*

    Listen in to hear about the recent update to the USPSTF CRC screening recommendations for average risk patients, including starting screening at age 45. This video will also provide an overview of the evidence that supports the new screening age and the potential impact of offering choice in CRC screening.

    Dr. Paul Limburg, a gastroenterologist with over 20 years of experience in clinical practice and the Chief Medical Officer for Screening at Exact Sciences, shares insights on how this update may impact CRC screening in your practice.

     

    Listen in to hear about the recent update to the USPSTF CRC screening recommendations for average risk patients, including starting screening at age 45. This video will also provide an overview of the evidence that supports the new screening age and the potential impact of offering choice in CRC screening.

    Dr. Paul Limburg, a gastroenterologist with over 20 years of experience in clinical practice and the Chief Medical Officer for Screening at Exact Sciences, shares insights on how this update may impact CRC screening in your practice.

     
    Download transcript

    Dr. Paul Limburg,
    Chief Medical Officer,
    Screening at Exact Sciences

    Dr. Limburg holds the academic rank of Professor of Medicine in the Mayo Clinic College of Medicine and serves as Chief Medical Officer for Screening at Exact Sciences.

    His previous Mayo Clinic leadership roles include Co-Leader of the Cancer Prevention and Control Program, Medical Director for Global Business Solutions, Medical Director for the Office of Health & Well-Being, Physician Lead for Prediction & Prevention in the Center for Innovation, and Research Director for the Healthy Living Program, among others. Dr. Limburg has served on several enterprise-wide committees at Mayo Clinic, including the Management Team and the Clinical Practice Committee.

    Read more

    With respect to his research activities, Dr. Limburg is Principal Investigator for the Cancer Prevention Network, an international, multicenter clinical trial consortium funded by the U. S. National Cancer Institute since 2003. He is a Fellow in the American Gastroenterological Association, an inductee into the honorary American Society for Clinical Investigation, and a member of the Sigma Xi scientific research honor society. His primary research interests include screening innovation, cancer chemoprevention, and molecular epidemiology. To date, Dr. Limburg has published over 140 peer-reviewed articles and 19 book chapters.

    Dr. Limburg earned his BA degree in chemistry from Augustana College (Sioux Falls, SD), MD degree from Mayo Medical School, and MPH degree from the Johns Hopkins School of Hygiene and Public Health. He completed his Internal Medicine residency and Gastroenterology & Hepatology fellowship training at the Mayo Graduate School of Medicine. Dr. Limburg also completed an advanced fellowship in Preventive Oncology at the U. S. National Cancer Institute.

    Dr. Limburg has received numerous awards and honors throughout his career, including a Cancer Prevention Laurel for Dedication to Community Programs from the Cancer Research and Prevention Foundation of America, a Career Development Award from the National Cancer Institute, and the Karis Award from Mayo Clinic. Dr. Limburg was selected to serve as Chair for the 2013 Frontiers in Cancer Prevention Research Program Committee (American Association for Cancer Research) and is widely recognized for his clinical, research, and leadership contributions in the field of cancer prevention.

  • Exact Sciences Laboratories Virtual Lab Tour

    Take this virtual tour for a sneak peek inside Exact Sciences Laboratories in Madison, Wisconsin. Learn how this innovative, customer-focused, mission-driven facility delivers colorectal cancer screening results for patients nationwide with Cologuard. You will see that no matter how far apart we are, patients are still within reach.
    Take this virtual tour for a sneak peek inside Exact Sciences Laboratories in Madison, Wisconsin. Learn how this innovative, customer-focused, mission-driven facility delivers colorectal cancer screening results for patients nationwide with Cologuard. You will see that no matter how far apart we are, patients are still within reach.
     
Join us for our upcoming events on screening for CRC.